May 16, 2022
Athira Issues Statement in Response to Richard A. Kayne’s Suspension of His Proxy Contest
May 16, 2022
Athira Pharma Presents Preclinical Data at the 2022 Peripheral Nerve Society (PNS) Annual Meeting
May 12, 2022
Athira Pharma Reports First Quarter 2022 Financial Results and Provides Pipeline and Business Updates
May 11, 2022
Athira Urges Shareholders to Support its Director Nominees at May 19 Annual Meeting
May 9, 2022
Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease
May 5, 2022
Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Athira Shareholders Vote “FOR” All of Athira’s Highly Qualified Director Nominees
May 5, 2022
Athira Mails Letter to Shareholders Emphasizing the Company’s Strong Position and Qualified Board as it Enters Pivotal Chapter
May 4, 2022
Leading Independent Proxy Advisory Firm ISS Recommends that Athira Shareholders Vote on Athira’s WHITE Proxy Card
April 26, 2022
Athira Files Investor Presentation Highlighting Successful Execution of its Strategy and Highly Qualified Board and Leadership
April 20, 2022
Athira Mails Letter to Shareholders Highlighting the Strength of its Board and Record of Deliberate Board Refreshment
Displaying 21 - 30 of 93